new warnings for patients taking Cylert (pemoline)

July 1999

You'll see new warnings for patients taking Cylert (pemoline).

Abbott now recommends that patients sign a consent form before starting Cylert...and get liver function tests EVERY TWO WEEKS.

Cylert is no longer recommended for initial therapy of attention deficit disorder...due to the risk of hepatotoxicity.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

first national guidelines for treating chronic stable angina
Infectious Diseases restricting the use of Trovan (trovafloxacin)
Infectious Diseases hepatitis B vaccine can be given ONCE A YEAR for 3 doses
Women's Health LOWER doses of estrogen to prevent osteoporosis
Women's Health Many women are afraid that estrogen replacement therapy increases the risk of breast cancer
Women's Health tamoxifen and raloxifene for preventing breast cancer
new warnings for patients taking Cylert (pemoline)
Paxil (paroxetine) is now approved for social phobia
Wellbutrin SR for weight loss
new treatments for Restless Legs Syndrome (RLS)
"andro" supplements DON'T build muscle
Sunscreens controversy over the SPF ratings on sunscreens
Bipolar Disorder Neurontin (gabapentin) and Lamictal (lamotrigine) for bipolar disorder
Bipolar Disorder omega-3 fatty acids for bipolar disorder
Men's Health new concerns about using Viagra (sildenafil) in patients taking HIV protease inhibitors
Men's Health now Pygeum africanum is the latest herb that's being promoted for benign prostatic hyperplasia
Gastroenterology warning patients not to drink grapefruit juice while taking Propulsid (cisapride)
Practice no longer market Hismanal (astemizole)